e-ISSN: Pending
Negative / Null Result Report

Incidence of SARS-CoV-2 in Patients with Rheumatic Diseases on Hydroxychloroquine, Compared with the Incidence of SARS-CoV-2 in Controls on a Prophylactic Dose of Hydroxychloroquine

Jordhani M; Ruci D; Jordhani P; Kalo T · 2025 · Preprint

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract (excerpt)

Background: Hydroxychloroquine (HCQ) is a disease-modifying antirheumatic drug used in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other autoimmune diseases. Although HCQ reduces SARS-CoV-2 replication in vitro at…

Excerpt shown for reference under fair use — read the full paper at the publisher.

Read full paper at publisher

Hosted by the publisher — may require access.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: Europe PMC · DOI 10.20944/preprints202509.1673.v1